Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii

Journal of Antibiotics

Volumn 69, Issue 6, 2016, Pages 415-421

  Tran, Thien B ^a   Cheah, Soon Ee ^a   Yu, Heidi H ^a   Bergen, Phillip J ^a   Nation, Roger L ^a   Creek, Darren J ^a   Purcell, Anthony ^a   Forrest, Alan ^b   Doi, Yohei ^c   Song, Jiangning ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSANTEL; POLYMYXIN B; ANTHELMINTIC AGENT; ANTIINFECTIVE AGENT; SALICYLANILIDE DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; DRUG EFFECTS; DRUG REPOSITIONING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTHELMINTICS; ANTI-BACTERIAL AGENTS; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; SALICYLANILIDES;

EID: 84976642882     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2015.127     Document Type: Article

References (53)

1. Boucher, H. W. et al. 10 x '20 Progress-development of new drugs active against gramnegative bacilli: An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56, 1685-1694 (2013).
2. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E. & Li, J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 8, 711-724 (2013).
3. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582 (2008).
4. Dudhani, R. V., Turnidge, J. D., Nation, R. L. & Li, J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65, 1984-1990 (2010).
5. Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284-3294 (2011).
6. Poulikakos, P., Tansarli, G. S. & Falagas, M. E. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: A systematic review. Eur. J. Clin. Microbiol. Infect. Dis. (2014).
7. Cai, Y., Chai, D., Wang, R., Liang, B. & Bai, N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67, 1607-1615 (2012).
8. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
9. Li, J.et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50, 2946-2950 (2006).
10. Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971-4977 (2010).
11. Pelletier, M. R. et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 57, 4831-4840 (2013).
12. Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect 18, 268-281 (2012).
13. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement (M100-S22). (2012).
14. Bergen, P. J. et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55, 5134-5142 (2011).
15. Pillai, S. K., Moellering, R. C. & Eliopoulos, G. M in Antibiotics in Laboratory Medicine (ed. Victor Lorian) Ch. 9, (Lippincott Williams & Wilkins, 2005).
16. Cheah, S. E., Li, J., Nation, R. L. & Bulitta, J. B. Novel rate-Area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Antimicrob. Agents Chemother. 59, 381-388 (2015).
17. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
18. Vincent, J. L. et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323-2329 (2009).
19. Kunz, A. N. & Brook, I. Emerging resistant Gram-negative aerobic bacilli in hospitalacquired infections. Chemotherapy 56, 492-500 (2010).
20. Li, J. et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6, 589-601 (2006).
21. Falagas, M. E. & Kasiakou, S. K. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333-1341 (2005).
22. Ko, K. S. et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60, 1163-1167 (2007).
23. Owen, R. J., Li, J., Nation, R. L. & Spelman, D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59, 473-477 (2007).
24. Tan, C. H., Li, J. & Nation, R. L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 51, 3413-3415 (2007).
25. Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect. Dis. 15, 225-234 (2015).
26. Martin, R. J. Modes of action of anthelmintic drugs. Vet. J. 154, 11-34 (1997).
27. Gloeckner, C. et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc. Natl. Acad. Sci. USA 107, 3424-3429 (2010).
28. Williamson, R. L. & Metcalf, R. L. Salicylanilides: A new group of active uncouplers of oxidative phosphorylation. Science 158, 1694-1695 (1967).
29. Omura, S Ivermectin: 25 years and still going strong. Int J. Antimicrob. Agents 31, 91-98 (2008).
30. Michiels, M., Meuldermans, W. & Heykants, J. The metabolism and fate of closantel (Flukiver) in sheep and cattle. Drug Metab. Rev. 18, 235-251 (1987).
31. Mohammed-Ali, N. A. & Bogan, J. A. The pharmacodynamics of the flukicidal salicylanilides, rafoxanide, closantel and oxyclosanide. J. Vet. Pharmacol. Ther. 10, 127-133 (1987).
32. Sandri, A. M. et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J. Antimicrob. Chemother. 68, 674-677 (2013).
33. Zavascki, A. P., Goldani, L. Z., Li, J. & Nation, R. L. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother. 60, 1206-1215 (2007).
34. Lean, S. S. et al. Prevalence and genetic characterization of carbapenem-And polymyxin-resistant Acinetobacter baumannii isolated from a tertiary hospital in Terengganu, Malaysia. ISRN Microbiol. 2014, 953417 (2014).
35. Freire, M. P. et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl. Infect. Dis. 16, 369-378 (2014).
36. Velkov, T. et al. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun. 20, 350-363 (2014).
37. Moskowitz, S. M. et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-Treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56, 1019-1030 (2012).
38. Urban, C., Tiruvury, H., Mariano, N., Colon-Urban, R. & Rahal, J. J. Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 55, 388-389 (2011).
39. Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo) 66, 571-591 (2013).
40. Schaberle, T. F. & Hack, I. M. Overcoming the current deadlock in antibiotic research. Trends Microbiol. 22, 165-167 (2014).
41. Conly, J. & Johnston, B. Where are all the new antibiotics? The new antibiotic paradox. Can. J. Infect. Dis. Med. Microbiol. 16, 159-160 (2005).
42. Poudyal, A. et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62, 1311-1318 (2008).
43. Keepers, T. R., Gomez, M., Celeri, C., Nichols, W. W. & Krause, K. M Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-Avibactam against beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58, 5297-5305 (2014).
44. Robin, F. et al. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM-And complex mutant TEM-producing clinical strains of Escherichia coli. J. Antimicrob. Chemother. 66, 1052-1056 (2011).
45. Hlasta, D. J. et al. Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Bioorg Med. Chem. Lett. 8, 1923-1928 (1998).
46. Macielag, M. J. et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J. Med. Chem. 41, 2939-2945 (1998).
47. Rajamuthiah, R. et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE 9, e89189 (2014).
48. Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-Activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2010).
49. Hancock, R. E. & Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 43, 1317-1323 (1999).
50. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol 3, 238-250 (2005).
51. Pristovsek, P. & Kidric, J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: An NMR and molecular modeling study. J. Med. Chem. 42, 4604-4613 (1999).
52. Hale, J. D. & Hancock, R. E. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 5, 951-959 (2007).
53. Sampson, T. R. et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob. Agents Chemother. 56, 5642-5649 (2012).